Literature DB >> 31863529

Recognition of gluconeogenic enzymes; Icl1, Fbp1, and Mdh2 by Gid4 ligase: A molecular docking study.

Abdo A Elfiky1,2, Alaa M Ismail1, Wael M Elshemey1,3.   

Abstract

The pro/N-degron pathway is an evolved protein degradation pathway through the ubiquitin-proteasome system. It is a vital pathway to attain protein homeostasis inside the liver cells with varying glucose levels. N-terminal proline exists in more than 300 proteins in Saccharomyces cerevisiae, but only three of them are the gluconeogenic enzymes; isocitrate lyase (Icl1), fructose-1,6-bisphosphatase (Fbp1), and malate dehydrogenase (Mdh2). The present in silico study aims to structurally illustrate the binding of Icl1 enzyme to Gid4 ligase concerning its peers; Fbp1 and Mdh2. Based on the molecular docking scores and interactions, one can attribute the binding stability of Gid4 with degrons, to peptides of length six up to eight from the N-terminal. Moreover, the percent change in the docking score provides a rationale for the unique Gid4-Icl11-4 interaction. The present study provides insights on the binding attitude of Gid4 ligase to degrons of different lengths, so one will consider in designing peptidomimetics to target Gid4 ligase.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  Gid4 E3 ligase; gluconeogenic enzymes; molecular docking; pro/N-end rule; protein degradation; structural bioinformatics

Mesh:

Substances:

Year:  2019        PMID: 31863529     DOI: 10.1002/jmr.2831

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  2 in total

1.  Host-cell recognition through GRP78 is enhanced in the new UK variant of SARS-CoV-2, in silico.

Authors:  Abdo A Elfiky; Ibrahim M Ibrahim
Journal:  J Infect       Date:  2021-01-22       Impact factor: 6.072

2.  Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19.

Authors:  Şevki Adem; Volkan Eyupoglu; Ibrahim M Ibrahim; Iqra Sarfraz; Azhar Rasul; Muhammad Ali; Abdo A Elfiky
Journal:  Comput Biol Med       Date:  2022-03-26       Impact factor: 6.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.